Sepsis News and Research

Latest Sepsis News and Research

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Following a Priority Review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through five years for active immunization against invasive pneumococcal disease, a bacterial infection that can include meningitis (inflammation of the coverings of the brain and spinal cord), sepsis (bloodstream infection), bacteremic pneumonia, pleural empyema (accumulation of pus in the cavity surrounding the lungs) and bacteremia (bacteria in the blood).

22 Dec 2009

New findings reveal POPG lipid can prevent RSV infection in lungs

Researchers at National Jewish Health have discovered that a naturally occurring lipid in the lung can prevent RSV infection and inhibit spread of the virus after an infection is established. RSV is the major cause of hospitalization for children in the first two years of life, and is increasingly recognized as a dangerous pathogen in adults with chronic lung diseases, the elderly, and immunocompromised individuals. Currently, there is no effective vaccine for the virus.

22 Dec 2009

Medela announces award recipients from November Virtual Human Milk Collection Campaign

Medela announced today the award recipients from its November Virtual Human Milk (breastmilk) Collection Campaign in honor of the March of Dimes' National Prematurity Awareness Month. More than 4,100 participated in the campaign, voting for their preferred Neonatal Intensive Care Unit.

18 Dec 2009

BioMS Medical invests in Spectral Diagnostics to advance treatment for sepsis

Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.

18 Dec 2009

Nitric oxide opens up new treatment option for septic shock

Scientists at VIB and Ghent University in Flanders, Belgium have found an unexpected ally for the treatment of septic shock, the major cause of death in intensive care units.

16 Dec 2009

Pfizer's Prevenar 13 granted European marketing authorization

The European Commission has granted Pfizer Inc. a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disease includes sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema.

11 Dec 2009

HSMR helps identify sepsis as an area of concern for Canadian hospitals

A new study shows that in 2008-2009 more than 9,300 patients died of sepsis, a condition resulting from the body's response to severe infection, in Canadian hospitals outside Quebec.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

New evidence finds link between nutrition, obesity and immune system

Fresh evidence that fatty food is bad for our health has come to light: mice fed a lard-based diet over a long period got worse at fighting bacteria in the blood, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg.

8 Dec 2009

Deaths from opioid use in Ontario have doubled, according to new study

Deaths from opioid use in Ontario have doubled-from 13.7 deaths per million residents in 1991 to 27.2 deaths per million residents in 2004-according to a new study led by physicians at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES) in Toronto.

8 Dec 2009

New data from Allos Therapeutics' FOLOTYN trial for PTCL

Allos Therapeutics, Inc. today reported a new analysis of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN

Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

4 Dec 2009

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Gloucester Pharmaceuticals announced today that ISTODAX® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL).

4 Dec 2009

PEG polymer may prevent GI injury during cancer radiotherapy

A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage.

3 Dec 2009

Sepsis, a serious infection, remains a major threat to 'late preterm' infants

Sepsis is a serious infection that is a major cause of death in very premature infants. But sepsis is also a threat in "late preterm" infants born just a few weeks prematurely, according to a study in the December issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

3 Dec 2009

MSC's Quality Initiative Programs to be highlighted at the 2009 IHI National Forum

Medical Simulation Corporation (MSC) will highlight its full menu of Quality Initiative Programs at the 2009 IHI National Forum, December 7-9, 2009, in Orlando, Florida. MSC is the first simulation company to introduce simulation-based education programs that help healthcare providers bridge the gap between measurement and achievement of publicly reported patient safety and quality initiatives.

2 Dec 2009